Fig. 3: mTOMC1 regulated mRNA stability of USP7 through m6A modification.
From: mTORC1 accelerates osteosarcoma progression via m6A-dependent stabilization of USP7 mRNA
A Eight patients with high levels of E2 were collected. The E2 content in 8 OS tissues or normal tissues. B The corresponding E2 content between each OS tissues and normal tissues. C Immunoblot analysis of p-S6, and S6 in 8 OS tissues or normal tissues. D Quauntification of p-S6 protein expression in OS tissues or normal tissues (n = 8). E, F The formation and quantification of ASC speck in OS tissues or normal tissues (n = 8). G IHC analysis of the expression of CYP19a1 in OS tissues or normal tissues, scale bar: 50 µm. H Quantification analysis of CYP19a1 positive cells in OS tissues or normal tissues. I The relative expression of USP7 in OS tissues and normal tissues (n = 8). J The m6AqPCR assay was performed to analyze the m6A enrichment in 5′UTR, CDS, and 3’UTR of USP7 mRNA in vector or Raptor transfected U2OS cells. K Schematic illustrations of mutation in m6A motif in CDS of USP7. L F-Luc/R-Luc activity in vector or Raptor transfected U2OS cells following treatment with USP7-CDS-WT or USP7-CDS-MUT. M Lifetime USP7 mRNA levels in vector or Raptor transfected U2OS cells following treatment with 0.5 mg/mL of actinomycin D for 0–4 h. N Lifetime USP7 mRNA levels in shCtrl or shRaptor transfected U2OS cells following treatment with 0.5 mg/mL of actinomycin D for 0–4 h. O The USP7 and Raptor mRNA levels in in vector or Raptor transfected U2OS cells. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs control group. ns not significant.
